Hold Rating on Johnson & Johnson Amidst Growth, Competition, and Legal Challenges
TipRanks (Thu, 18-Apr 1:56 AM ET)
TipRanks (Thu, 18-Apr 12:30 AM ET)
Scotiabank upgrades Legend Biotech to sector outperform
Seeking Alpha News (Wed, 17-Apr 4:35 PM ET)
Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results
Benzinga (Wed, 17-Apr 1:51 PM ET)
TipRanks (Wed, 17-Apr 5:20 AM ET)
RBC Capital Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
TipRanks (Wed, 17-Apr 3:59 AM ET)
FDA approves Alvotech biosimilar of J&J top-selling drug Stelara
Seeking Alpha News (Tue, 16-Apr 6:22 PM ET)
Nasdaq, S&P, Dow end mixed after hawkish Powell further clouds rate cut expectations
Seeking Alpha News (Tue, 16-Apr 4:11 PM ET)
Steady Performance and Aligned Guidance Justify Hold Rating for Johnson & Johnson
TipRanks (Tue, 16-Apr 1:35 PM ET)
TipRanks (Tue, 16-Apr 1:30 PM ET)
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.
As of April 18, 2024, JNJ stock price climbed to $145.74 with 8,580,092 million shares trading.
JNJ has a beta of 0.57, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.15 to the broad based SPY ETF.
JNJ has a market cap of $350.94 billion. This is considered a Mega Cap stock.
Last quarter Johnson & Johnson reported $21 billion in Revenue and $2.71 earnings per share. This fell short of revenue expectation by $-27 million and exceeded earnings estimates by $.07.
In the last 3 years, JNJ stock traded as high as $186.69 and as low as $143.13.
The top ETF exchange traded funds that JNJ belongs to (by Net Assets): RAYD, VTI, VOO, SPY, IVV.
JNJ has underperformed the market in the last year with a price return of -9.2% while the SPY ETF gained +22.3%. JNJ has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.4% and -5.5%, respectively, while the SPY returned +6.1% and -3.8%, respectively.
JNJ support price is $143.41 and resistance is $146.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ stock will trade within this expected range on the day.